Sofinnova Investments, Inc.
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Sofinnova Investments, Inc. reported 53 stock positions worth $1.9 billion. Its top holding was Natera (NTRA) at 22.5% of the portfolio, followed by Vera Therapeutics (VERA, 6.4%) and Genmab A/S -SP ADR (GMAB, 5.9%). Compared with Q1 2026, it opened 11 new positions, sold out of 19, added to 12 and reduced 17. The biggest buy was Genmab A/S -SP ADR (GMAB, shares +438%) and the biggest sale an exit from Astrazeneca (AZN).
- Most Recent 13F
- Q2 2026
- Location
- Menlo Park, CA
- CIK
- 0001631134
- Portfolio Value
- $1.9B (Q2 2026)
- SEC Filing
- 0001104659-26-096982 ↗ filed Aug 14, 2026
Holdings Value
Holdings 53 stocks · $1.9B
| NTRA Natera Inc. | 22.48% | 1,550,280 | $420.8M | No change |
| VERA Vera Therapeutics Inc. | 6.40% | 2,793,987 | $119.9M | No change |
| GMAB Genmab A/S -SP ADR | 5.94% | 4,045,215 | $111.1M | Add +437.7% |
| JAZZ Jazz Pharmaceuticals PLC | 4.70% | 365,341 | $88.0M | Reduce -38.9% |
| RAPP Rapport Therapeutics Inc. | 4.24% | 1,904,408 | $79.4M | No change |
| SPTX Seaport Therapeutics Inc. | 4.14% | 3,564,871 | $77.4M | New |
| AVBP Arrivent Biopharma Inc. | 3.15% | 1,696,752 | $58.9M | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 3.06% | 1,717,505 | $57.3M | Reduce -45.4% |
| BIOA Bioage Labs Inc. | 3.00% | 2,293,788 | $56.2M | No change |
| BMY Bristol-Myers Squibb Co. | 2.70% | 876,970 | $50.5M | Reduce -55.9% |
| SUPN Supernus Pharmaceuticals Inc. | 2.57% | 1,036,328 | $48.2M | Add +8.6% |
| RYTM Rhythm Pharmaceuticals Inc. | 2.42% | 408,027 | $45.3M | Reduce -9.3% |
| GILD Gilead Sciences Inc. | 2.32% | 343,100 | $43.3M | New |
| UTHR United Therapeutics Corp. | 2.21% | 76,489 | $41.4M | Reduce -52.2% |
| COGT Cogent Biosciences Inc. | 2.14% | 1,035,148 | $40.1M | Reduce -51.0% |
| AXSM Axsome Therapeutics Inc. | 2.10% | 160,429 | $39.3M | Reduce -24.6% |
| IMTX Immatics NV | 1.99% | 3,669,346 | $37.2M | Add +1.1% |
| DYN Dyne Therapeutics Inc. | 1.97% | 1,658,384 | $36.8M | Add +1.5% |
| IMNM Immunome Inc. | 1.95% | 1,720,316 | $36.5M | Add +1.1% |
| IDYA Ideaya Biosciences Inc. | 1.84% | 925,119 | $34.5M | Reduce -18.3% |
| ANAB Anaptysbio Inc. | 1.78% | 493,536 | $33.3M | Add +98.8% |
| NKTR Nektar Therapeutics | 1.76% | 471,763 | $32.9M | Reduce -7.4% |
| PHVS Pharvaris NV | 1.63% | 881,299 | $30.5M | Add +7.7% |
| RCUS Arcus Biosciences Inc. | 1.56% | 945,690 | $29.2M | Add +2.5% |
| INBX Inhibrx Biosciences Inc. | 1.53% | 303,103 | $28.7M | Reduce -25.4% |
| BMRN Biomarin Pharmaceutical Inc. | 1.10% | 358,568 | $20.5M | Reduce -54.1% |
| MANE Veradermics Inc. | 0.98% | 148,993 | $18.3M | Add +103.2% |
| ALC Alcon Inc. filed as ALCON AG | 0.92% | 255,824 | $17.2M | Reduce -65.0% |
| INSM Insmed Inc. | 0.90% | 158,398 | $16.9M | Reduce -54.2% |
| EWTX Edgewise Therapeutics Inc. | 0.83% | 380,923 | $15.5M | Reduce -1.4% |
| NRIX Nurix Therapeutics Inc. | 0.68% | 524,098 | $12.7M | New |
| DSGN Design Therapeutics Inc. | 0.67% | 865,135 | $12.5M | New |
| DFTX Definium Therapeutics Inc. | 0.64% | 255,903 | $12.0M | Reduce -25.6% |
| TRAX First Tracks Biotherapeutics | 0.61% | 565,199 | $11.4M | New |
| ABT Abbott Laboratories | 0.60% | 122,998 | $11.2M | New |
| IRON Disc Medicine Inc. | 0.57% | 146,239 | $10.7M | Add +86.7% |
| TENX Tenax Therapeutics Inc. | 0.39% | 500,039 | $7.3M | Add +379.0% |
| SION Sionna Therapeutics Inc. | 0.34% | 144,432 | $6.4M | New |
| ABSI Absci Corp. | 0.21% | 337,400 | $3.9M | New |
| MIRM Mirum Pharmaceuticals Inc. | 0.17% | 27,591 | $3.2M | No change |
| JBIO Jade Biosciences Inc. | 0.13% | 107,391 | $2.4M | No change |
| SVRA Savara Inc. | 0.12% | 364,763 | $2.2M | No change |
| PRAX Praxis Precision Medicines I | 0.12% | 6,440 | $2.2M | Reduce -89.9% |
| SEPN Septerna Inc. | 0.09% | 47,506 | $1.6M | No change |
| OKUR Onkure Therapeutics Inc. Class A | 0.08% | 321,692 | $1.5M | Add +127.0% |
| SGMT Sagimet Biosciences Inc. Class A | 0.07% | 166,667 | $1.3M | New |
| WVE Wave Life Sciences Ltd. | 0.06% | 189,253 | $1.1M | No change |
| AKTS Aktis Oncology Inc. | 0.06% | 32,436 | $1.0M | New |
| TYRA Tyra Biosciences Inc. | 0.06% | 32,267 | $1.0M | Reduce -84.2% |
| BOLT Bolt Biotherapeutics Inc. | 0.03% | 137,721 | $530K | No change |
| NXTC Nextcure Inc. | 0.02% | 222,654 | $356K | No change |
| IMA Imagenebio Inc. | 0.01% | 31,884 | $188K | No change |
| HTFL Heartflow Inc. | 0.01% | 5,079 | $149K | New |
Options reported separately and not counted above: RARE calls ($16.7M), ISRG calls ($15.9M), GMED calls ($15.8M), EXEL puts ($13.8M).
Portfolio Sells Q1 2026 → Q2 2026
| AZN Astrazeneca PLC | Sold out | 0.00% | −4.51 |
| BMY Bristol-Myers Squibb Co. | Reduce -55.9% | 2.70% | −3.34 |
| UTHR United Therapeutics Corp. | Reduce -52.2% | 2.21% | −2.54 |
| BIIB Biogen Inc. | Sold out | 0.00% | −2.11 |
| CELC Celcuity Inc. | Sold out | 0.00% | −2.09 |
| COGT Cogent Biosciences Inc. | Reduce -51.0% | 2.14% | −1.94 |
| INSM Insmed Inc. | Reduce -54.2% | 0.90% | −1.93 |
| ALC Alcon Inc. | Reduce -65.0% | 0.92% | −1.84 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −1.52 |
| DXCM Dexcom Inc. | Sold out | 0.00% | −1.24 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -54.1% | 1.10% | −1.12 |
| JAZZ Jazz Pharmaceuticals PLC | Reduce -38.9% | 4.70% | −0.96 |
| PRAX Praxis Precision Medicines I | Reduce -89.9% | 0.12% | −0.91 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −0.89 |
| SYK Stryker Corp. | Sold out | 0.00% | −0.73 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −0.66 |
| CMPX Compass Therapeutics Inc. | Sold out | 0.00% | −0.55 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −0.43 |
| TNGX Tango Therapeutics Inc. | Sold out | 0.00% | −0.41 |
| AXGN Axogen Inc. | Sold out | 0.00% | −0.35 |
| TYRA Tyra Biosciences Inc. | Reduce -84.2% | 0.06% | −0.34 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.30 |
| RARE Ultragenyx Pharmaceutical Inc. | Reduce -45.4% | 3.06% | −0.24 |
| HRMY Harmony Biosciences Holdings | Sold out | 0.00% | −0.21 |
| PCVX Vaxcyte Inc. | Sold out | 0.00% | −0.15 |
| ESTA Establishment Labs Holdings | Sold out | 0.00% | −0.10 |
| ACAD Acadia Pharmaceuticals Inc. | Sold out | 0.00% | −0.09 |
| NKTR Nektar Therapeutics | Reduce -7.4% | 1.76% | −0.08 |
| IDYA Ideaya Biosciences Inc. | Reduce -18.3% | 1.84% | −0.05 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −0.02 |
| ZYME Zymeworks Inc. | Sold out | 0.00% | −0.00 |
| INBX Inhibrx Biosciences Inc. | Reduce -25.4% | 1.53% | +0.17 |
| EWTX Edgewise Therapeutics Inc. | Reduce -1.4% | 0.83% | +0.22 |
| AXSM Axsome Therapeutics Inc. | Reduce -24.6% | 2.10% | +0.30 |
| DFTX Definium Therapeutics Inc. | Reduce -25.6% | 0.64% | +0.32 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -9.3% | 2.42% | +0.46 |
Portfolio Buys Q1 2026 → Q2 2026
| GMAB Genmab A/S -SP ADR | Add +437.7% | 5.94% | +4.92 |
| SPTX Seaport Therapeutics Inc. | New | 4.14% | +4.14 |
| GILD Gilead Sciences Inc. | New | 2.32% | +2.32 |
| ANAB Anaptysbio Inc. | Add +98.8% | 1.78% | +1.09 |
| MANE Veradermics Inc. | Add +103.2% | 0.98% | +0.75 |
| NRIX Nurix Therapeutics Inc. | New | 0.68% | +0.68 |
| DSGN Design Therapeutics Inc. | New | 0.67% | +0.67 |
| TRAX First Tracks Biotherapeutics | New | 0.61% | +0.61 |
| ABT Abbott Laboratories | New | 0.60% | +0.60 |
| RCUS Arcus Biosciences Inc. | Add +2.5% | 1.56% | +0.56 |
| DYN Dyne Therapeutics Inc. | Add +1.5% | 1.97% | +0.48 |
| PHVS Pharvaris NV | Add +7.7% | 1.63% | +0.47 |
| SION Sionna Therapeutics Inc. | New | 0.34% | +0.34 |
| IRON Disc Medicine Inc. | Add +86.7% | 0.57% | +0.32 |
| TENX Tenax Therapeutics Inc. | Add +379.0% | 0.39% | +0.30 |
| ABSI Absci Corp. | New | 0.21% | +0.21 |
| IMTX Immatics NV | Add +1.1% | 1.99% | +0.20 |
| SUPN Supernus Pharmaceuticals Inc. | Add +8.6% | 2.57% | +0.10 |
| IMNM Immunome Inc. | Add +1.1% | 1.95% | +0.08 |
| SGMT Sagimet Biosciences Inc. Class A | New | 0.07% | +0.07 |
| AKTS Aktis Oncology Inc. | New | 0.06% | +0.06 |
| OKUR Onkure Therapeutics Inc. Class A | Add +127.0% | 0.08% | +0.05 |
| HTFL Heartflow Inc. | New | 0.01% | +0.01 |
Options Activity Q1 2026 → Q2 2026
| IWM iShares Russell 2000 ETF | put | Sold out | 600,000 | $148.8Mbefore exit |
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 1,050,000 | $134.1Mbefore exit |
| QQQ Invesco QQQ Trust Series 1 | put | Sold out | 150,000 | $86.6Mbefore exit |
| IBB iShares Biotechnology ETF | put | Sold out | 475,000 | $80.2Mbefore exit |
| UTHR United Therapeutics Corp. | put | Sold out | 80,300 | $47.6Mbefore exit |
| CELC Celcuity Inc. | put | Sold out | 300,000 | $34.2Mbefore exit |
| AXSM Axsome Therapeutics Inc. | put | Sold out | 200,000 | $33.8Mbefore exit |
| PFE Pfizer Inc. | call | Sold out | 800,000 | $22.5Mbefore exit |
| LQDA Liquidia Corp. | put | Sold out | 500,000 | $18.9Mbefore exit |
| RARE Ultragenyx Pharmaceutical Inc. | call | Add +42.9% | 500,000 | $16.7M |
| ISRG Intuitive Surgical Inc. | call | New | 40,000 | $15.9M |
| GMED Globus Medical Inc. Class A | call | New | 200,000 | $15.8M |
| EXEL Exelixis Inc. | put | Add +1.1% | 254,200 | $13.8M |
| REPL Replimune Group Inc. | call | Sold out | 1,015,400 | $7.8Mbefore exit |
| CMPX Compass Therapeutics Inc. | call | Sold out | 500,000 | $2.6Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 53 | $1.9B | NTRA, VERA, GMAB, JAZZ, RAPP |
| Q1 2026 | 61 | $2.0B | NTRA, BMY, JAZZ, VERA, UTHR |
| Q4 2025 | 60 | $2.3B | NTRA, JAZZ, AZN, VERA, BMY |
| Q3 2025 | 55 | $1.6B | NTRA, GILD, VERA, UTHR, JAZZ |
| Q2 2025 | 55 | $1.5B | NTRA, GILD, LLY, JAZZ, VERA |
| Q1 2025 | 59 | $1.3B | NTRA, SYK, VERA, JAZZ, MDT |
| Q4 2024 | 60 | $1.4B | NTRA, VERA, GILD, ABBV, JAZZ |
| Q3 2024 | 56 | $1.2B | NTRA, VERA, NVO, AZN, IDYA |
| Q2 2024 | 71 | $1.6B | NTRA, VERA, ASND, NVO, EW |
| Q1 2024Amended | 66 | $1.7B | NTRA, VERA, ASND, AEROVATE THERAPEUTICS INC, MRK |